Utility of metabolic stability screening:: comparison of in vitro and in vivo clearance

被引:89
作者
Clarke, SE [1 ]
Jeffrey, P [1 ]
机构
[1] GlaxoSmithKline Pharmaceut, Drug Metab & Pharmacokinet, Welwyn Garden City AL6 9AR, Herts, England
关键词
D O I
10.1080/00498250110057350
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The ability of hepatic microsomal metabolic stability assessments to predict in vivo clearance in rat has been retrospectively evaluated for 1163 compounds from 48 programmes of chemistry. Using a simple binary classification system, the in vivo clearances of similar to 64% of the compounds were correctly classified. 2. About 24% of compounds were metabolically stable yet had clearance greater than half of liver blood flow in vivo. This might be expected as microsomes only contain a limited number of fully functioning drug-metabolizing enzymes and cannot be expected to account for extrahepatic or non-metabolic clearance processes. 3. About 13% of compounds had in vivo clearances of less than half liver blood flow despite being classified as metabolically unstable. Despite overcoming metabolic instability, these compounds had other undesirable properties and were generally more highly bound to plasma proteins, had smaller volumes of distribution (and shorter half-lives despite their clearance) and were more inhibitory against the major human cytochrome P450s. 4. Taking plasma protein binding into consideration reduced the proportion of misclassified low-clearance compounds but did not improve the overall success appreciably. Somewhat surprisingly, human microsomes were nearly as effective as rat microsomes at classifying rat in vivo clearance.
引用
收藏
页码:591 / 598
页数:8
相关论文
共 11 条
[1]   BASIC PRINCIPLES OF PHARMACOKINETICS [J].
BENET, LZ ;
ZIAAMIRHOSSEINI, P .
TOXICOLOGIC PATHOLOGY, 1995, 23 (02) :115-123
[2]   Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans [J].
Carlile, DJ ;
Hakooz, N ;
Bayliss, MK ;
Houston, JB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (06) :625-635
[3]   LAURIC ACID AS A MODEL SUBSTRATE FOR THE SIMULTANEOUS DETERMINATION OF CYTOCHROME-P450 2E1 AND 4A IN HEPATIC MICROSOMES [J].
CLARKE, SE ;
BALDWIN, SJ ;
BLOOMER, JC ;
AYRTON, AD ;
SOZIO, RS ;
CHENERY, RJ .
CHEMICAL RESEARCH IN TOXICOLOGY, 1994, 7 (06) :836-842
[4]   Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450 [J].
Crespi, CL ;
Miller, VP ;
Penman, BW .
ANALYTICAL BIOCHEMISTRY, 1997, 248 (01) :188-190
[5]  
Houston JB, 2000, DRUG METAB DISPOS, V28, P246
[6]   Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices [J].
Houston, JB ;
Carlile, DJ .
DRUG METABOLISM REVIEWS, 1997, 29 (04) :891-922
[7]   Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25
[8]  
Obach RS, 1999, DRUG METAB DISPOS, V27, P1350
[9]   Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective [J].
Rodrigues, AD .
PHARMACEUTICAL RESEARCH, 1997, 14 (11) :1504-1510
[10]   Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques [J].
Schneider, G ;
Coassolo, P ;
Lavé, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) :5072-5076